Within the CUP or CRP group, it was crucial to further compare biomarkers and combination panels between the MLC and PLC groups to explore if the therapeutic efficiency of TrxR and other TMs were affected by the type of liver cancer. The gene discussed is CRP; the disease is liver cancer.